XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.25.3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Accounting Policies [Abstract] |
SCHEDULE OF NUMERATOR AND DENOMINATOR OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE | The following is a reconciliation of the numerator and denominator of basic and diluted net income (loss) per share for the three and nine months ended September 30, 2025 and 2024. SCHEDULE OF NUMERATOR AND DENOMINATOR OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |
Net Income (loss) from continuing operations |  | $ | 834,493 |  |  | $ | (180,488 | ) |  | $ | 714,186 |  |  | $ | (2,872,286 | )
Net Loss from discontinued operations |  |  | (31,246,601 | ) |  |  | (2,702,564 | ) |  |  | (36,672,075 | ) |  |  | (5,339,011 | )
Less: Net loss from continuing operations attributable to noncontrolling interests |  |  | (955 | ) |  |  | (1,740 | ) |  |  | (5,197 | ) |  |  | (3,224 | )
Less: Net loss from discontinued operations attributable to noncontrolling interests |  |  | - |  |  |  | (23,544 | ) |  |  | - |  |  |  | (82,107 | )
Net loss attributable to Sanara MedTech shareholders |  | $ | (30,411,153 | ) |  | $ | (2,857,768 | ) |  | $ | (35,952,692 | ) |  | $ | (8,125,966 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average shares, basic |  |  | 8,646,668 |  |  |  | 8,517,381 |  |  |  | 8,610,538 |  |  |  | 8,468,394 |
Dilutive effect of stock options |  |  | 31,013 |  |  |  | - |  |  |  | 31,013 |  |  |  | - |
Dilutive effect of unvested shares |  |  | 263,053 |  |  |  | - |  |  |  | 266,014 |  |  |  | - |
Weighted average shares, diluted |  |  | 8,940,734 |  |  |  | 8,517,381 |  |  |  | 8,907,565 |  |  |  | 8,468,394 |
Net income (loss) per share, basic: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Continuing operations |  | $ | 0.10 |  |  | $ | (0.02 | ) |  | $ | 0.08 |  |  | $ | (0.34 | )
Discontinued operations |  |  | (3.62 | ) |  |  | (0.32 | ) |  |  | (4.26 | ) |  |  | (0.62 | )
Net income (loss) per share of common stock, basic |  | $ | (3.52 | ) |  | $ | (0.34 | ) |  | $ | (4.18 | ) |  | $ | (0.96 | )
Net income (loss) per share, diluted: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Continuing operations |  | $ | 0.09 |  |  | $ | (0.02 | ) |  | $ | 0.08 |  |  | $ | (0.34 | )
Discontinued operations |  |  | (3.49 | ) |  |  | (0.32 | ) |  |  | (4.12 | ) |  |  | (0.62 | )
Net income (loss) per share of common stock, diluted |  | $ | (3.40 | ) |  | $ | (0.34 | ) |  | $ | (4.04 | ) |  | $ | (0.96 | )
SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE | The following table summarizes the shares of common stock that were potentially issuable but were excluded from the computation of diluted net loss per share of common stock for the three and nine months ended September 30, 2024, as such shares would have had an anti-dilutive effect: SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE
|  | September 30, 2024 |
Stock options(a) |  |  | 31,013 |
Warrants(b) |  |  | 16,725 |
Unvested restricted stock |  |  | 224,392 |
| (a) | Shares underlying stock options assumed pursuant to the merger agreement with Precision Healing, Inc. (“Precision Healing”) in April 2022.
| (b) | Shares underlying warrants assumed pursuant to the merger agreement with Precision Healing in April 2022.
SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES | Revenue streams from product sales and royalties for the three and nine months ended September 30, 2025 and 2024 are summarized below. SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Soft tissue repair products |  | $ | 23,424,126 |  |  | $ | 18,863,335 |  |  | $ | 66,618,023 |  |  | $ | 52,586,945 |
Bone fusion products |  |  | 2,909,693 |  |  |  | 2,808,264 |  |  |  | 8,954,144 |  |  |  | 7,779,209 |
Royalties |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 906 |
Total Net Revenue |  | $ | 26,333,819 |  |  | $ | 21,671,599 |  |  | $ | 75,572,167 |  |  | $ | 60,367,060 |
SCHEDULE OF PROPERTY AND EQUIPMENT | SCHEDULE OF PROPERTY AND EQUIPMENT
|  | Useful Life |  | September 30, 2025 |  |  | December 31, 2024 |
Computers |  | 3-5 years |  | $ | 251,180 |  |  | $ | 295,963 |
Office equipment |  | 3-7 years |  |  | 247,535 |  |  |  | 216,491 |
Furniture and fixtures |  | 5-10 years |  |  | 335,108 |  |  |  | 346,508 |
Leasehold improvements |  | 2-5 years |  |  | 213,852 |  |  |  | 181,968 |
Property and equipment, gross |  |  |  |  | 1,047,675 |  |  |  | 1,040,930 |
Less accumulated depreciation |  |  |  |  | (630,467 | ) |  |  | (608,613 | )
Property and equipment, net |  |  |  | $ | 417,208 |  |  | $ | 432,317 |
SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION | SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION
|  | Amount |
Balance at December 31, 2024 |  | $ | 748,001 |
Additions |  |  | 1,355,603 |
Revaluation of earnout liabilities |  |  | (1,875,603 | )
Balance at September 30, 2025 |  | $ | 228,001 |

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details
Name: | us-gaap_PropertyPlantAndEquipmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1 + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration